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Abstract Systemic inflammation and infections are
associated with neurodegenerative diseases. Unfortunately,
the molecular bases of this link are still largely undiscov-
ered. We, therefore, review how inflammatory processes
can imbalance membrane homeostasis and theorize how
this may have an effect on the aggregation behavior of the
proteins implicated in such diseases. Specifically, we
describe the processes that generate such imbalances at the
molecular level, and try to understand how they affect
protein folding and localization. Overall, current knowl-
edge suggests that microglia pro-inflammatory mediators
can generate membrane damage, which may have an
impact in terms of triggering or accelerating disease
manifestation.
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Introduction
Neurodegenerative diseases are familial and sporadic
conditions characterized by the progressive dysfunction
of the nervous system [1, 2]. In some cases, the origins
of these diseases can be related to destabilizing muta-
tions in proteins, which become less stable and more
prone to aggregating or interacting with undesired part-
ners [3]. In these examples, neurodegenerative conditions
have a genetic, inheritable component and individuals
develop them at an earlier age. One of the most studied
cases is Alzheimer’s disease (AD), where mutations in
the amyloid precursor protein (APP) can lead to the
aggregation of the processed amyloid beta peptide (Ab),
generating characteristic plaques in the brain [4]. Fur-
thermore, in amyotrophic lateral sclerosis (ALS) and
Parkinson’s disease (PD), mutations in superoxide dis-
mutase and a-synuclein, respectively, may cause the
aggregation of these proteins and affect the function of
motor neurons, causing tremors and muscle paralysis [5,
6].
However, many patients suffering from late onset neu-
rodegenerative diseases lack a predefined genetic
background. Indeed, it is widely recognized that such dis-
orders are multifactorial and associated with both an
individual genome and environmental conditions [7].
Although the molecules and signaling pathways
involved in the inflammatory response have been widely
characterized, it is still unclear how they influence the
development of neurodegenerative diseases and are
linked to environmental challenges. In this paper, we
review how inflammatory mechanisms can have an
impact on membrane homeostasis and how this may
perturb the key proteins associated with neurodegenera-
tive disorders.
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Inflammation in neurodegenerative diseases
Though direct infection or hyper-sensitivity to foreign
proteins may cause an intrinsic inflammation, the brain is
also vulnerable to damage in response to systemic
inflammation as infiltration of immune cells and mediators
can lead to profound structural and functional changes [8].
The blood–brain barrier (BBB) isolates the central ner-
vous system (CNS) from the circulating blood, creating a
privileged environment. While this is required to maintain
brain homeostasis, it does not mean that the brain is
depleted of immune cells [9]. Also, the CNS is not com-
pletely isolated from blood circulation [10] as cytokines
may: (1) by-pass the BBB at the circumventricular organs
and mobilize resident macrophages; (2) activate the brain
endothelial cells and signal the microglia within the par-
enchyma; (3) activate the sensory afferents of the vagus
nerve communicating with neurons and, finally, (4) be
actively transported by the endothelium across the BBB.
Microglia cells, as resident macrophages of the CNS, play
a central role in the innate immune response [11, 12]. In the
absence of damage, resting microglia have a ramified
morphology and constantly survey the environment in
order to identify potentially harmful signals that require a
response [13]. When this happens, the microglia take on an
amoeboid morphology, changing the expression of surface
receptors and secreting pro- and anti-inflammatory medi-
ators (e.g., chemokines and cytokines), recruitment factors,
and chemicals such as reactive oxygen species (ROS). In
this state, the microglia cells are described as activated.
Fig. 1 Inflammation can disturb the membrane and promote protein
aggregation. Activated microglia cells produce peptides, proteins and
reactive species of oxygen and nitrogen that can perturb membrane
homeostasis. The binding of peptides and the oxidation of phospho-
lipids can increase the gel phase and raft domains, triggering protein
aggregation and disease. a APP is in equilibrium between its native
and cleaved forms, the latter of which is generated by the action of
different secretases (purple). In the non-lipid raft portion, which is
abundant in unsaturated phospholipids (light green), cleavage by a-
secretase produces soluble APP and membrane-bound CTFa. How-
ever, in terms of lipid rafts, where the membrane domains are rich in
cholesterol (red), glycosphingolipids (orange) and saturated lipids
(dark green), APP cleavage by b-secretase can generate APP-sb and
CTFb. The latter peptide can subsequently be processed by c-
secretase to produce the aggregation prone Ab peptide (blue).
b Changes in membrane composition can modify the phosphorylation
pattern (purple circles) of the tau protein and promote its aggregation
propensity. Ab aggregates and tau neurofibrillar tangles are charac-
teristic of AD. c Alterations in the distribution of a-synuclein between
different membrane domains can trigger a self-assembling process,
which can be accelerated by lipid peroxidation (dark blue). a-
synuclein oligomers can damage neuron membranes and promote the
development of PD. d Superoxide dismutase (SOD) can also bind to
different membrane domains in different compositions, and its
distribution between them can modulate its aggregation propensity.
Specifically, an increase in the content of saturated fatty acids and
oxidized lipids can support SOD-oligomerization, thereby promoting
the development of ALS
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Bacteria can activate microglia and promote memory
impairment in young mice through a mechanism that
involves interleukin-1, and the high-mobility group protein
B1 [14]. For example, a single sublethal injection of
lipopolysaccharide (LPS) can impair behavior and memory
in mice, reduce the proliferation of neural stems cells and
induce microglia invasion and activation to the hip-
pocampus [15]. Severe systemic inflammation, such as
sepsis, also leads to an increased production of the nuclear
factor jB [16] that changes the microglia phenotype [17].
Most interesting, there is convincing evidence that
increased amounts of inflammatory biomarkers are
observed before the clinical onset of dementia. For
example, Kuo and co-workers [18] found that an increase
in C-reactive protein in serum was increased 5 years before
the clinical onset of dementia. In another case, Buchhave
and co-workers showed that TNF receptors TNFR1 and
TNFR2 are also associated with the development of
dementia 4–6 years before to disease manifestation [19].
In this section, we aim to review how inflammation is
connected to the most studied neurodegenerative diseases.
We also highlight recent studies that support the notion that
triggering the brain immune system, either during early
embryonic stages or by chronic activation at a later age,
can promote and/or accelerate the development of neu-
rodegenerative disorders.
Fig. 2 Membrane damage as an explanation on how microglia-
secreted mediators may promote protein aggregation. a When a
systemic infection is detected in the body, several inflammatory
mediators are released. Some of these can cross the blood–brain
barrier and stimulate microglial cells (purple). These cells change its
morphology and become activated, releasing pro-inflammatory
cytokines, ROS and other peptide mediators in the brain. When a
chronic inflammatory signal is present, microglia cells become
permanently primed, and the continued release of pro-inflammatory
mediators can damage the surrounding neuronal cells (yellow). In
turn, neuronal damage contributes to increasing the microglia
activators that further activate microglial cells, causing a dangerous,
self-sustaining activation cycle. b At the molecular level, ROS and
the binding of pro-inflammatory mediators to specific receptors
generate a transcriptional response in neurons. Moreover, ROS can
cause lipid peroxidation (dark blue), thus perturbing neuronal
membrane homeostasis, while the unspecific binding of peptide
mediators can alter membrane fluidity. Globally, the integrated
response to microglial secretions at the membrane level may lead to
aggregation and protein mislocation. This may also trigger changes in
post-translational modifications, including the phosphorylation state
of several proteins such as a-synuclein, Ab and tau. Last but not least,
protein aggregates themselves or through the activation of receptors
and signaling complexes (e.g. TLR2 or NLRP3 inflammasome) may
generate a self-perpetuating mechanism of increased membrane
damage and aggregation
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Inflammation in Alzheimer’s disease
Alzheimer’s disease is a multifactorial, neurodegenerative
illness that is manifest as a cognitive impairment and
behavioral disorder [20]. Histopathological analyses of the
brains of patients with the condition reveal nerve and
synapse loss, but also two characteristic lesions: plaques
containing aggregated Ab peptide and tau neurofibrillar
tangles [21].
A significant number of aged individuals with AD suffer
from more than one systemic disease [22] suggesting that
systemic inflammation might be a risk factor for AD. In
fact, systemic inflammation and acute infections have been
associated with cognitive decline in patients with AD [23,
24] and genome-wide analyses suggest that several genes
that increase the risks for sporadic Alzheimer’s disease
encode factors that regulate inflammatory reactions [25].
In a recent study, Krstic and colleagues developed a
model to demonstrate that viral infections are related to late
onset AD. The team treated isogenic mice with either the
viral mimic polyriboinosinic-polyribocytidilic acid
(PolyI:C) or a placebo, and measured neuropathological
changes during aging [26]. Only the mice treated with the
RNA analog developed amyloid plaques and experienced
significant impairments in their working memory at older
ages. These results suggest not only that inflammation and
infection can increase the probability of developing AD,
but also that environmental conditions can trigger neu-
rodegenerative disorders irrespective of the genetic
background.
The same authors suggest that during healthy aging
misfolded and aberrant proteins are directed to budding
structures called intracellular varicosities, which are later
extruded, engulfed and degraded by microglia cells [27].
According to the authors’ model, under chronic inflam-
matory stress, microglia cells become permanently
activated and cannot properly remove these deposits.
Thereafter, axonal varicosities swell and accumulate APP,
jeopardizing axonal transport. Moreover, activated micro-
glia secrete pro-inflammatory mediators and reactive
oxygen species that contribute to neuronal damage. Ulti-
mately, the aberrant processing of APP (misfolding stress)
and excessive neuronal damage (oxidative stress) promote
the formation of amyloid plaques that are released upon
neuron death.
Chronic inflammatory stimuli are also involved in tau
phosphorylation and tangle formation. Kitazawa and col-
leagues found an increase in the former at specific sites in
3xTg-AD transgenic mice after they were injected with
LPS, which also exacerbates pre-tangle pathology in a
cyclin kinase 5-dependent mechanism [28]. Although in
their experiments the progressive activation of microglia
was found to correlate with the onset of fibrillar aggregates,
the causal relationship between immune activation, tau
phosphorylation and fibrillation is still unclear. In another
study, Bhaskar and his colleagues observed that intraperi-
toneally administered LPS induced Iba1? activated
microglia promoting tau hyperphosphorylation in non-
transgenic mice [29]. They also noted that mice lacking the
fractalkine receptor CX3CR1 displayed enhanced tau
phosphorylation and aggregation, as well as behavioral
impairments. When LPS activates microglia, it induces the
release of fractalkine that binds to the microglia G-coupled
fractalkine receptor, downregulating the activation and
dampening the toxic effects of the activated microglia [29].
In fact, knocking out CX3CR1 in various mouse models of
AD worsens the phenotype [30] and aggravates cognitive
deficits [31]. As a result, it is possible that chronic neu-
roinflammation leads to the microglia being in a
permanently activated state that is insensitive to fractalkine
signaling, thus endangering neurons.
Inflammation in Parkinson’s disease
Parkinson’s disease is the second most common neurode-
generative disorder after AD, and causes a slow and
progressive degeneration of dopaminergic neurons in the
substantia nigra and a later degeneration in the central
cortex [32]. Patients affected by this disease have charac-
teristic intracellular protein inclusions called Lewy bodies
that contain a-synuclein, among other proteins. The origin
of these inclusions and the causes of neuronal loss are not
fully understood. Patients with PD have an increased level
of pro-inflammatory mediators in their cerebrospinal fluid
(including TNF-a, IL-1b and IL-6) and a presence of
microglial cells in the substantia nigra [33]. These changes
are associated with the progression of the disease, but it is
not known whether they are involved in the pathological
process or are a consequence of neuronal degeneration.
Experiments in animal models have revealed that the
injection of LPS leads to an accumulation of a-synuclein
and the progressive degeneration of the dopamine nigros-
triatal system, causing motor impairments [34]. Those
responsible for this research determined that neuroinflam-
mation induced by LPS generates damage caused by the
S-nitrosylation/nitration of mitochondrial proteins. These
events are followed by the progressive degeneration of
dopaminergic neurons in the nigrostriatal system [34].
Recent studies suggest that cytokine IL-1 plays a central
role in mediating the functional changes induced by LPS,
but the precise mechanism by which microglial activation
occurs and leads to motor neuron impairment remains to be
determined [35].
As observed in AD, fractalkine receptor CX3CR1-
knockout mouse models of PD also reveal the worsening of
the phenotype [30], suggesting that the modulation of
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inflammation by fractalkine signaling can protect against
microglial neurotoxicity. Interestingly, Nash and his co-
workers found that soluble fractalkine is capable of
reducing the dopaminergic neuron loss caused by human a-
synuclein over-expression [36].
Inflammation in amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis is one of the most common
late onset neurogenerative diseases, with a prevalence of
*5 per 100,000 individuals. It is characterized by the
selective deterioration of motor neurons, which leads to the
progressive atrophy of skeletal muscles [37].
Autopsies of ALS patients have revealed that active
demyelination and neurodegeneration are present in those
with marked brain inflammation [38]. Recently, Frakes and
colleagues found that NF-jB signaling pathway is acti-
vated in ALS, predominantly in microglia [39]. Moreover,
the deletion of microglia NF-jB signaling rescues motor
neurons in mice with ALS by inhibiting pro-inflammatory
activation [39]. NF-jB is a protein complex that plays a
central role in regulating the immune response to infection,
and is also activated in the microglia cells of patients
suffering from AD and PD [40, 41].
In 2009, Saijo and his co-workers discovered an orphan
receptor called Nurr1 that functions as a key component of
a negative feedback loop in both microglia and astrocytes.
Nurr1 acts by recruiting the CoREST corepressor to NF-jB
target genes, regulating NF-jB turnover and restoring its
expression to a basal state. In this context, the absence of
Nurr1 makes cells susceptible to the toxicity caused by
mutations in superoxide dismutase 1 (SOD1), which is an
enzyme linked to ALS [42]. Interestingly, Nurr1 is also
related to other neurodegenerative pathologies, and pro-
motes exaggerated and prolonged inflammatory responses
that accelerate the loss of dopaminergic neurons in
response to a-synuclein overexpression [43]. Furthermore,
the number of Nurr1-expressing cells significantly declines
in an age-dependent manner that is concomitant with
increased Ab accumulation [44].
Inflammation in Huntington’s disease
Other neurodegenerative diseases have also been associ-
ated with inflammation. An example is Huntington’s
disease (HD), where the aggregation of huntingtin causes
motor impairments and neuropsychiatric disorders [45].
Similar to other neurodegenerative pathologies, cells
expressing mutant huntingtin with an expanded polyglu-
tamine (polyQ) repeat have elevated NF-jB activity [46].
Moreover, in cortico-striatal slices and primary neuronal
culture models, the microglia are localized in the vicinity
of neurons expressing mutant huntingtin genes and have
increased levels of the pro-inflammatory cytokine IL-6
[47].
Taken together, all of this evidence highlights the fact
that neuroinflammation is a general hallmark of neurode-
generative diseases, and that a permanent activation of the
brain immune system could increase the probability of
developing such conditions. Even more relevant, the liter-
ature suggests that neurodegenerative diseases may share
inflammatory pathways, including the activation of the NF-
jB pathway and the deregulation of fractalkine signaling.
In the next section, we attempt to elucidate how
inflammation is connected to both protein aggregation and
cell damage.
Inflammation and membrane damage
Membranes are transcendental structures in organisms,
because they compartmentalize the cell and organize cel-
lular processes. The cell membrane is a lipid bilayer that
envelops the entire cell, physically separating the internal
milieu from the extracellular environment. The cell mem-
brane acts a barrier, but also enables the transport of
molecules and ions and allows cell-to-cell communication.
Lipid bilayers must be impermeable to molecules and
ions from the surrounding environment, but, at the same
time, they need to be fluid enough to allow dynamic pro-
cesses like protein traffic within the membrane [48]. This
delicate balance can be easily disturbed by changes in lipid
structure and composition. This occurs, for example, due to
oxidative damage or when proteins and chemicals affect
the membrane recycling cycle. Overall, these processes
modify the bilayer fluidity and alter the membrane orga-
nization, i.e., they globally disturb membrane homeostasis
[49]. This homeostasis is critical for ensuring the curvature
of the membrane, correct receptor signaling, endocytosis,
exocytosis and organelle biogenesis.
When human microglia are activated during inflamma-
tion, they produce reactive species of oxygen and nitrogen
(ROS) to kill invading pathogens. However, ROS can also
affect surrounding host cells, inducing neurotoxicity [50,
51]. In these situations, as the most external part of the cell,
membranes can sustain a great deal of damage from these
ROS. Peroxidation processes target lipids within the
plasma membrane, in particular, polyunsaturated phos-
pholipids that modify membrane fluidity. Such changes can
affect the interaction of proteins and lipids across the
membrane. For example, macrophages treated with
hydrogen peroxide increase both the gel phase and raft
domains, reducing overall membrane fluidity [52]. Similar
effects have also been described in other cell types, such as
T-lymphocytes and endothelial cells [53, 54]. Activated
microglia also secrete pro-inflammatory mediators like
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cytokines, interleukins and antimicrobial peptides. These
molecules can interact with the cell membrane, promoting
a structural rearrangement. Antimicrobial peptides, for
instance, can redistribute cholesterol, reduce membrane
fluidity and create pores, damaging the membrane [55–57].
Lipid homeostasis is critical for protein activity, cell
membrane recycling and accurate signaling. In fact, lipid
composition alterations in the aged brain can have a dra-
matic effect on maintaining synaptic functions, including
membrane fusion processes, neurotransmitter receptor
dynamics and survival/death signaling pathways [58].
An uncontrolled inflammatory response can, therefore,
damage neurons by directly disturbing the cell membrane
homeostasis. Yet can this have an effect on the formation
of protein aggregates and the deposits observed in neu-
rodegenerative diseases? There are two important reasons
suggesting that this may be the case:
(1) All the known proteins related to brain neurode-
generative diseases need to bind to membranes to exert
their functions:
i. In AD, APP is an integral membrane protein, and the
tau association with the plasma membrane is crucial for its
correct phosphorylation [59].
ii. In PD, a-synuclein plays a role in lipid transport and
synaptic membrane biogenesis [60].
iii. In ALS, the binding of superoxide dismutase 1
(SOD1) to the membrane is required for adequate copper
distribution [61].
(2) Several observations suggest that membranes pro-
vide a singular environment for amyloid-like aggregates:
i. The diffusion of proteins in membranes occurs in two
dimensions, which enhances the probability of protein–
protein interactions [62].
ii. Membranes support the better growth of amyloid fibrils
[63]. Also the presence of lipid rafts may provide a singular
environment to regulate fibril formation and aggregation [64].
iii. Oligomers generally interact with membranes and
cause membrane damage (e.g., pore formation) [65].
Accordingly, inflammation may cause an imbalance in
membrane homeostasis and, in doing so, affect the aggre-
gation process of the proteins that are related to well-
known neurodegenerative diseases. In the following sec-
tions, we review how this can be linked to specific
neurodegenerative pathologies.
Membrane perturbation in Alzheimer’s disease
APP is in equilibrium when it is between its native form
and the cleavage between different secretases [66]. It can
be cleaved by a-secretase, leading to a free APP-sa peptide
and a membrane-bound CTFa in the non-amyloidogenic
cascade. This process takes place in the non-lipid raft
portion of the membrane, and the species produced are
non-pathogenic. However, lipid raft-associated APP can be
recruited in the endosomes and cleaved by b-secretase
(also known as BACE), generating a soluble peptide
known as APP-sb and a membrane-bound peptide called
CTFb. The latter is then processed by the lipid raft-asso-
ciated c-secretase to generate toxic Ab species. These
endosomes can be later degraded in lysosomes or re-ex-
ported to the membrane through the membrane recycling
process that secretes Ab fragments to the extracellular
medium.
In this scenario, as Ab formation is raft dependent, the
situations that shift the distribution of APP to lipid rafts
could increase Ab production, triggering AD [67]. For
example, a decrease in membrane fluidity due to lipid
oxidation could lead to the APP accumulating in the gel
phase, increasing APP cleavage by c-secretase and toxic
Ab peptide levels (Fig. 1a).
Much evidence supports the notion that a decrease in
membrane fluidity could enhance the production of Ab and
accelerate its aggregation:
(1) Saturated phospholipids and gel phase membranes
support the growth of amyloid intermediates better [63,
68].
(2) Cholesterol exposure increases Ab production by
clustering APP and BACE together [69, 70].
(3) AD predominantly affects the cerebral cortex and
hippocampus, which is a region of the brain that is sig-
nificantly enriched in cholesterol when compared to other
areas such as the cerebellum [71].
(4) Diets lower in cholesterol and saturated lipids reduce
the risk of developing AD [72].
Membrane homeostasis imbalances can also be related
to tau aggregation. Maas and colleagues used a micro-
sphere separation process to isolate plasma membrane-
associated tau and reported that it was differentially
phosphorylated when compared with cytosolic tau [73].
More recently, Hernandez and her co-workers analyzed tau
phosphorylation after the incubation of SHSY-5Y cells
with Ab peptide [74]. The authors observed both an
increase in Tyr18 phosphorylated tau after 2 min of treat-
ment and a higher association with lipid rafts. After
10 min, they began to detect Ser396 and Ser404 phos-
phorylated tau, which became more intensively associated
with lipid rafts, suggesting a correlation between phos-
phorylation and raft association. In addition, several
authors have reported that tau aggregation is modulated by
the bilayer lipid composition [75, 76]; specifically, nega-
tively charged and oxidized phospholipids can increase its
aggregation [76, 77]. Consequently, changes in membrane
dynamics can affect protein folding and phosphorylation,
affecting the location, function and aggregation of tau
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(Fig. 1b). Indeed, tau intermediate aggregates may promote
neuronal damage through membrane disruption [76].
Membrane perturbation in Parkinson’s disease
a-Synuclein is a protein that is neuropathologically related
to PD, and promotes the loss of dopamine-producing
neurons in the mid-brain [78]. It is widely accepted that a-
synuclein forms toxic oligomeric conformations that dis-
rupt the synaptic function and eventually lead to neuronal
death [79].
The binding of a-synuclein to membranes is funda-
mental for its natural function, but this interaction can also
start a nucleation process that generates seeds that can later
grow by incorporating cytosolic monomers [80].
Unfortunately, the precise membrane location of
a-synuclein is still controversial. Fortin and her co-workers
demonstrated that lipid rafts settle the synaptic localization
of a-synuclein [81]. Meanwhile, in a recent study, Pranke
and colleagues revealed that a-synuclein does not localize
widely to the plasma membrane, but only to vesicular
clusters closely associated with it [82]. As a result,
a-synuclein distribution between the different lipid phases
of the plasma membrane may impact its function and its
aggregation properties (Fig. 1c).
Lipid peroxidation in the brain substantia nigra has been
reported in patients suffering from PD [83]. Similar to
other lipids, cholesterol is also affected by oxidative stress,
which can change the aggregation properties of the proteins
residing in lipid rafts. Bosco and his co-workers detected
the presence of oxidized cholesterol metabolites in Lewy
bodies, and proposed that oxidative stress produces
cholesterol aldehydes that may cause a-synuclein aggre-
gation [84]. In the same direction, Giasson and colleagues
identified a selective and specific nitration of a-synuclein
in both PD and dementia [85], and concluded that the
oxidative and nitrative damage caused by it are directly
linked to neurodegeneration. As the nitration of tyrosines in
the C-terminus of the protein may restrict its binding to the
membrane [86], it is possible that the oxidation and nitra-
tion processes could promote synapse damage and, at the
same time, release a-synuclein into the cytoplasm, where it
may aggregate due to the exposure of previously hidden
hydrophobic patches (Fig. 1c).
Membrane perturbation in amyotrophic lateral
sclerosis
Superoxide dismutase 1 is the best characterized gene of
the proteins that lead to ALS, which is a paralytic disorder
caused by the degeneration of motor neurons [87].
As described for APP, tau and a-synuclein, SOD1 also
has the ability to bind to membranes [61], with a significant
fraction associated with lipid rafts [88]. In fact, lipid
binding and oxidation processes can enhance SOD1
oligomerization and the formation of cytotoxic aggregates
[89, 90]. Accordingly, alterations in membrane dynamics
may redistribute SOD1, modulating its aggregation
propensity. For example, lipid peroxidation can generate
radicals in the membrane that promote the oligomerization
of the protein (Fig. 1d).
Other proteins have also been related to ALS, including
TDP-43, alsin and dynactin. To the best of our knowledge,
TDP-43 membrane-binding activities have not yet been
characterized. However, alsin and dynactin play relevant
roles in membrane traffic: alsin plays a part in cell mem-
brane organization and endocytosis, while dynactin is
essential for vesicle movement [91, 92].
Membrane perturbation in Huntington’s disease
Huntingtin is a large protein that is related to development
and apoptosis, and is neuropathologically linked to HD. Its
aggregation is due to the presence of a poly-Q repeat,
which is formed either by the configuration of hydrogen
bonds between amide residues or through the action of
transglutaminase [93]. It is believed that huntingtin
aggregates may cause neurodegeneration by sequestering
other essential proteins and disrupting the protein quality
control machinery [94].
Huntingtin is normally associated with membranes by
palmitoylation, which is essential for its function and traffic
inside the cell [95]. Bertoni and colleagues observed that
an expansion of the poly-Q repeat causes the migration of
the protein to lipid rafts, where it interacts with gp91, a
membrane NADPH-oxidase subunit. Gp91, in turn, stim-
ulates ROS production and DNA damage [96].
Additionally, the poly-Q aggregates are also able to induce
membrane damage [97].
Future perspectives
From the literature examined in this paper, it is reasonable
to conclude that perturbations at the membrane level may
have a major impact on the folding, location and function
of proteins and a direct implication in disease. Further-
more, membrane perturbation can also trigger functional
changes in membrane-anchored proteins [98] that may be
relevant for the progression of a disorder, including
G-coupled receptors that can alter Ab production and
degradation [99, 100].
Taking into consideration all the data reported above,
we suggest that neuroinflammation promoted by the dys-
functional actions of microglia can cause an imbalance in
membrane homeostasis, thus promoting or aggravating
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protein aggregation (Fig. 2). Additionally, amyloid aggre-
gates, mainly oligomers [101], can also destabilize
membranes [102] and contribute further to worsen
inflammation by activating the NLRP3 inflammasome and
Toll-like receptor 2 [103]. These events may, thus, generate
a self-perpetuating mechanism of increased membrane
damage and aggregation (Fig. 2).
If inflammation can effectively trigger or accelerate the
progression of neurodegenerative diseases it would provide
promising avenues for the development of new biomarkers
and drugs to fight these pathologies. Several authors have
already proposed that NLRP3 inflammasome inhibition
represents a new therapeutic intervention for the disease
[104]. In fact, small molecules have been designed to
inhibit the NLRP3 inflammasome for the treatment of
inflammatory diseases [105]. All these results are encour-
aging and bring us closer to an effective treatment for
neurodegenerative pathologies.
It is our view that comprehension of the link between
inflammation, membrane homeostasis and protein confor-
mational plasticity will lead to a better understanding of
diseases. Consequently, a multidisciplinary approach is
required:
(1) At the biochemistry and biophysics level to under-
stand how membrane interaction drives the conformational
switch of proteins.
(2) From a cell biology perspective to comprehend how
changes in membrane dynamics and composition are
translated into signaling processes and protein post-trans-
lational modifications.
(3) From an immunology point of view to identify and
characterize the cells and mediators responsible for this
membrane homeostasis imbalance. The results provided by
future studies in these areas will hopefully lead to the
development of new drugs and treatments for neurode-
generative diseases.
Last but not least, a more detailed comprehension of
inflammation in less prevalent diseases (e.g., HD, ALS)
may help to understand common as well as particular
molecular mechanisms involved in neurodegeneration.
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